for 4 PEP strategies: the current USPHS recommendations, triple drug therapy, zidovudine monotherapy or no prophylaxis. A …

disease. Results of a pivotal randomised study (DMP 266-006) comparing efavirenz- versus indinavir-based triple combination … with the indinavir-based regimen. In conclusion, current treatment guidelines for HIV infection recognise efavirenz … greater virological response to efavirenz- than indinavir-based triple combination therapy, and the efavirenz-based regimen …

indinavir and 2 nucleoside reverse transcriptase inhibitors (NRTIs; zidovudine and lamivudine) in HIV-positive patients. Design … dollars (1998 values) relative to initial therapy with the indinavir-containing regimen. Patients who receive efavirenz are …Objective: To compare the clinical and economic outcomes associated with triple therapy containing efavirenz or …

developed countries. Two nucleoside analogue reverse transcriptase inhibitors, such as lamivudine and zidovudine, plus a … for initial or second-line treatment. A combination formulation of lamivudine and zidovudine has recently become available …. Combination therapy with lamivudine and zidovudine (as dual therapy or in combination with another nucleoside analogue reverse …

lamivudine + (zidovudine or didanosine or zalcitabine or stavudine)]; and ERA-III [2 nucleoside reverse transcriptase inhibitors …) regimens, denoted as ERA-I [zidovudine + (didanosine or zalcitabine)]; ERA-II [stavudine + (didanosine or zalcitabine) or …

carcinoma. Lamivudine is the only oral antiviral agent approved for the treatment of patients with chronic hepatitis B …. Lamivudine is useful in a wide range of patients with chronic hepatitis B and ongoing viral replication. In patients with … compensated liver disease treated for 52 weeks in multicenter randomized, double-blind clinical studies, lamivudine 100 mg …